Nasdaq

bioMérieux: BIOFIRE® Respiratory Panel 2.1 (RP2.1) with SARS-CoV-2 Obtains FDA Emergency Use Authorization

MARCY L’ÉTOILE, France--(BUSINESS WIRE)-- Regulatory News: bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary ...
Nasdaq

bioMérieux submits enhanced BIOFIRE® BCID2 Panel for FDA clearance

MARCY L’ÉTOILE, France--(BUSINESS WIRE)-- Regulatory News: bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, announces that BioFire Diagnostics, its molecular biology ...
FierceBiotech

BioFire Diagnostics keeps identity in $450M bioMérieux deal

BioFire Diagnostics may have agreed to sell itself to French diagnostics giant bioMérieux for $450 million, but the company plans to keep its name and senior management and continue growing at its ...
FierceBiotech

BioMérieux closes BioFire Diagnostics deal for $450M plus debt

French diagnostics giant bioMérieux finalized its acquisition of U.S.-based BioFire Diagnostics on Thursday. Under the agreement, bioMérieux will pay $450 million and will also assume BioFire's net ...
WRAL TechWire

BioMerieux to acquire BioFire Diagnostics for $450M

Diagnostics company bioMerieux has reached an agreement to acquire molecular biology company BioFire Diagnostics for $450 million in a move intended to strengthen the French company’s position in ...
FiercePharma

BioMérieux snags BioFire Diagnostics in $450M buy

French diagnostics developer bioMérieux is ponying up $450 million for the newly renamed BioFire Diagnostics in a move that helps consolidate its position in infectious disease testing. Chairman and ...
Reuters

BioMerieux buys diagnostics rival BioFire for $450 mln

PARIS, Sept 4 (Reuters) - French biotech firm BioMerieux will buy privately-owned U.S. rival BioFire Diagnostics for $450 million, in a deal aimed at consolidating its position as a major player in ...